Effect of PD solutions on patient outcome

Contributions to Nephrology

Volumn 150, Issue , 2006, Pages 90-96

  Lo, Wai Kei ^a  

^a TUNG WAH HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

DIALYSIS FLUID; GLUCOSE;

HUMAN; METABOLISM; METHODOLOGY; MORTALITY; PERITONEAL DIALYSIS; REVIEW;

DIALYSIS SOLUTIONS; GLUCOSE; HUMANS; PERITONEAL DIALYSIS;

EID: 33745271850     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000093507     Document Type: Review

References (14)

1. Rippe B, Simonsen O, Heimbürger O, et al: Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 2001;59:348-357.
2. Williams JD, Topley N, Craig KJ, et al: The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004;66:408-418.
3. Kim YL, Do JY, Park SH, et al: Low glucose degradation products dialysis solution modulates the levels of surrogate markers of peritoneal inflammation, integrity, and angiogenesis: preliminary report. Nephrology 2003;8:S28-S32.
4. Lee HY, Park HC, Seo BJ, et al: Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005;25:248-255.
5. Cooker LA, Luneburg P, Holmes CJ, et al: Interleukin-6 levels decreases in effluent from patients dialyzed with bicarbonate/lactate-based peritoneal dialysis solutions. Perit Dial Int 2001;21(suppl 3):S102-S107.
6. Tranaeus A: A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution - clinical benefits. Perit Dial Int 2000;20:216-523.
7. Fusshoeller A, Plail M, Grabensee, Plum J: Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective randomized study. Nephrol Dial Transplant 2004;19:2101-2106.
8. Li FK, Chan LY, Woo JC, et al: A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAD. Am J Kidney Dis 2003;42:176-186.
9. Tjiong HL, van den Berg JW, Wattimena JL, et al: Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol 2005;16:1486-1493.
10. Johnson DW, Arndt M, O'Shea A, et al: Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload. BMC Nephrol 2001;2:2.
11. Davies S, Woodrow G, Donovan K, et al: Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003;14:2338-2344.
12. le Poole CT, Welten AG, Weijmer MC, et al: Initiating CAPD with a regimen low in glucose and glucose degradation products, with icodextrin and amino acids (NEPP) is safe and efficacious. Perit Dial Int 2005;25(suppl 3):S64-S68.
13. Marshall J, Jennings P, Scott A, et al: Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 2003;64:1480-1486.
14. Biesen WV, Boer W, Greve BD, et al: A randomized clinical trial with a 0.6% amino acid/1.4% glycerol peritoneal dialysis solution. Perit Dial Int 2004;24:222-230.